{"type":"trials","record":{"id":42247,"source_id":"clinicaltrials-gov","external_id":"NCT02228304","title":"Study of the Intravitreal Implantation of NT-503-3 Encapsulated Cell Technology (ECT) for the Treatment of Recurrent Choroidal Neovascularization (CNV) Secondary to Age-related Macular Degeneration (AMD)","brief_summary":"Prospective, multi-center 2-stage study. Stage 1 (Phase I) is open-label with all patients treated with the NT-503-3 ECT implant. Stage 1 (Phase I) patients will undergo explantation at year 2. Those who, in the opinion of the investigator, are still candidates for continued anti-VEGF therapy will be re-implanted with a new NT-503-3 investigational product and followed for an additional 12 weeks before study exit. Stage 2 (Phase II) is a separate, randomized, masked phase during which eligible patients will be randomized to the NT-503-3 group or the control group. Clinical Hypotheses: * NT-503-3 ECT is comparable to Eylea® injected intravitreally every 8 weeks in the prevention of vision loss due to recurrent CNV secondary to AMD * NT-503-3 ECT has an acceptable safety profile","overall_status":"Terminated","phases":["PHASE1","PHASE2"],"study_type":"INTERVENTIONAL","sponsor":"Neurotech Pharmaceuticals","enrollment":42,"countries":["United States","Israel"],"start_date":"2014-09-01","completion_date":"2016-04-01","last_update_date":"2022-07-18","source_url":"https://clinicaltrials.gov/study/NCT02228304","editorial_summary":"A registered PHASE1, PHASE2 study indexed because it matched monitored longevity research terms. Registry status: Terminated. Registration does not establish safety or effectiveness.","first_seen_at":"2026-09-25T01:25:30.378222+00:00","last_seen_at":"2026-09-25T06:20:47.789+00:00","metadata":{"sex":"ALL","acronym":null,"age_range":"50 Years","comparator":"Eylea® injected intravitreally every 8 weeks","organization":"Neurotech Pharmaceuticals","interventions":["NT-503-3 ECT implantation","Eylea® injected intravitreally administered every 8 weeks"],"registry_source":"ClinicalTrials.gov","outcome_measures":["Percentage of patients with less than a 3-line loss of BCVA in ETDRS letters — Week 52 and Week 108","Change from baseline in best corrected visual acuity (BCVA) — Week 52","Change from baseline in macular thickness as determined by Spectral Domain Optical Coherence Tomography (sdOCT) — Up to…","Mean (median) number of Eylea® injections and number of patients requiring Eylea® injections for rescue therapy — Up to…"],"design_description":"RANDOMIZED · PARALLEL · TREATMENT · TRIPLE","source_has_results":false},"controlled_terms":["Macular Degeneration","NT-503-3 ECT implantation","Eylea® injected intravitreally administered every 8 weeks"],"relevance_confidence":80,"source_quality_score":100,"freshness_score":50,"publication_state":"published","match_explanation":"Title contains controlled term: age-related macular degeneration.","quality_checked_at":"2026-09-25T06:20:59.355028+00:00","duplicate_cluster_key":"id:nct02228304","duplicate_of_id":null,"evidence_snapshot":{"status":"structured","version":1,"duration":"2014-09-01 to 2016-04-01","comparator":"Eylea® injected intravitreally every 8 weeks","confidence":"structured-source","population":"ALL · 50 Years","provenance":{"duration":"start_date and completion_date","comparator":"registry arm fields","population":"registry eligibility fields","intervention":"registry intervention fields","participants":"enrollment","study_design":"study_type and registry design fields","evidence_stage":"phases","reported_outcome":"not available","outcomes_measured":"registry outcome-measure fields"},"generated_at":"2026-09-25T06:20:47.940Z","intervention":["NT-503-3 ECT implantation","Eylea® injected intravitreally administered every 8 weeks"],"participants":42,"study_design":"RANDOMIZED · PARALLEL · TREATMENT · TRIPLE","subject_scope":"Human clinical study registration","evidence_stage":"PHASE1, PHASE2","safety_context":"Eligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians.","source_support":"Structured registry protocol metadata; no finding-level conclusion is generated.","main_limitation":"This is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.","reported_outcome":null,"outcomes_measured":["Percentage of patients with less than a 3-line loss of BCVA in ETDRS letters — Week 52 and Week 108","Change from baseline in best corrected visual acuity (BCVA) — Week 52","Change from baseline in macular thickness as determined by Spectral Domain Optical Coherence Tomography (sdOCT) — Up to…","Mean (median) number of Eylea® injections and number of patients requiring Eylea® injections for rescue therapy — Up to…"],"regulatory_context":"Trial registration is not regulatory approval and does not establish that an intervention is available."},"clinical_trial_topics":[{"topic_slug":"vision-aging","is_published":true,"match_reasons":["Title contains controlled term: age-related macular degeneration.","Title supplies longevity context: age-related.","Study type is explicitly identified as INTERVENTIONAL."],"matched_fields":["title","title context","study type"],"relevance_score":80,"intelligence_topics":{"name":"Vision ageing","slug":"vision-aging"}}],"content_sources":{"name":"ClinicalTrials.gov","homepage_url":"https://clinicaltrials.gov/"}},"canonical_url":"https://www.immortal.life/trials/42247","automation_disclosure":"Generated automatically from cited source metadata. No scientist, clinician, researcher, editor, or human reviewer evaluates this publication before release."}